Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

CONMED Corp (CNMD): Scopia Capital Isn’t Done Buying Shares

Page 1 of 22

Two weeks after Matt Sirovich and Jeremy Mindich‘s Scopia Capital first revealed a large position in CONMED Corporation (NASDAQ:CNMD), the investment firm has filed another 13D on the company which shows that it has continued to buy shares of it since. The firm now owns 2.09 million shares of the medical supplies company, up from 1.69 million shares as of the February 23 filing which revealed the new holding. You can see the latest ownership information in the table below.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
SCOPIA PX 542,427 2,093,148 542,427 2,093,148 542,427 2.0%
SCOPIA PARTNERS 15,099 2,093,148 15,099 2,093,148 15,099 Less than 1%
SCOPIA HEALTH CARE 41,342 41,342 41,342 Less than 1%
SCOPIA WINDMILL FUND 382,036 382,036 382,036 1.4%
SCOPIA INTERNATIONAL MASTER FUND 95,331 95,331 95,331 Less than 1%
SCOPIA PX INTERNATIONAL MASTER FUND 688,144 688,144 688,144 2.5%
SCOPIA HEALTH CARE INTERNATIONAL MASTER FUND 300,900 300,900 300,900 1.1%
SCOPIA CAPITAL GP 2,065,279 2,065,279 2,065,279 7.5%
SCOPIA CAPITAL MANAGEMENT 2,093,148 2,093,148 2,093,148 7.6%
SCOPIA MANAGEMENT, INC 2,093,148 2,093,148 2,093,148 7.6%
MATTHEW SIROVICH 2,093,148 7.6%
JEREMY MINDICH 2,093,148 7.6%
Matt Sirovich And Jeremy Mindich
Matt Sirovich And Jeremy Mindich
Scopia Capital

Page 1 of 22 SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
§ 240.13d-2(a)
(Amendment No. 2)1
CONMED Corporation
(Name of Issuer)
Common Stock, $0.01 par value
(Title of Class of Securities)
207410101
(CUSIP Number)
SAMANTHA NASELLO
SCOPIA CAPITAL MANAGEMENT LP
152 West 57th Street, 33rd Floor
New York, New York 10019
(212) 370-0303
STEVE WOLOSKY
OLSHAN FROME WOLOSKY LLP
Park Avenue Tower
65 East 55th Street
New York, New York 10022
(212) 451-2300

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)
March 7, 2016
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.
Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.
_______________
1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Conmed Corp (NASDAQ:CNMD)
Trade (NASDAQ:CNMD) Now!
Page 1 of 22

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!